Loading news...
Exelixis and Summit Therapeutics could have significant catalysts this year. Both have drug candidates that could drive strong financial results for a while.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock. Awards were made to 20 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA.
Regencell led last week's large-cap losers as Figma, Atlassian and Trip.com slid on downgrades, probes and broader tech weakness.
Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the seventeen ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, nine have issued a buy recommendation and one has
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only approved product, Casgevy.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Co.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ.
Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committe.
In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion.
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down.
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential.
Akeso stands out as a diversified Chinese biotech with strong licensing deals, a robust pipeline, and growing revenues from multiple approved therapies. Unlike SMMT, AKESF benefits from milestone payments, retains Chinese commercialization rights, and faces less development risk from single-asset dependence. SMMT's commercialization ability is questionable, with leadership concerns, cash burn, and the loss of key partnerships like Pfizer undermining its prospects.